{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-21-000210","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2021-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.702336+00:00","generated_at":"2026-06-30T05:44:51.863471+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Regen Biopharma discloses full IP portfolio status with patent grants, allowances, and revival efforts","bullets":["Granted US patents: BORIS gene silencing (8,263,571), NR2F6 anti-tumor methods (11,053,503), NR2F6 screening (10,088,485), NR2F6 modulation (9,091,696).","Notice of allowance received for antigen-specific mRNA cancer vaccine (app. 15/162,370).","Two patent assets in revival: siRNA cancer therapy (8,389,708) and universal donor cord blood killer cells (15/494,358).","Active applications include NR2F6 inhibition combined with cannabidiol for cancer, angiogenesis, arthritis; small molecule NR2F6 modulators.","Zander Therapeutics licensed patent for canine dendritic cell immunotherapy (10,030,227)."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-21-000210","json":"https://secwatch.observer/filing/0001607062-21-000210.json","markdown":"https://secwatch.observer/filing/0001607062-21-000210.md","text":"https://secwatch.observer/filing/0001607062-21-000210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000210/0001607062-21-000210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000210/rgbp071321form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T05:44:51.863471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}